Abstract #1366

Distinguishing the Chemical Signature of Different IDH Mutations in Brain Tumor Patients at 7 Tesla

Uzay E Emir¹, Sarah Larkin², Nick de Pennington², Puneet Plaha³, Natalie Voets¹, James Mccullagh⁴, Richard Stacey³, Peter Jezzard¹, Stuart Clare¹, Christopher Schofield⁴, Tom Cadoux-Hudson³, and Olaf Ansorge²

¹FMRIB Centre, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, ³Department of Neurosurgery, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ⁴Department of Chemistry, University of Oxford, Oxford, United Kingdom

In this study, we show a proton magnetic resonance spectroscopy (¹H-MRS) acquisition scheme at 7T, enabling discernible 2-HG in the spectra of IDH-mutant patients acquired within 20s and quantify metabolic changes associated with the IDH mutation. Due to the increased sensitivity and specificity of this scheme at 7T, we demonstrate elevated 2-HG and Lactate accumulation in IDH2 R172K (mitochondrial) compared to the IDH1 R132H (cytosolic) mutant tumors in human brains noninvasively.

This abstract and the presentation materials are available to members only; a login is required.

Join Here